Monday, January 26, 2009

Merck KGaA: Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Phase III Pivotal Trial

›
• Two-year primary efficacy endpoint of CLARITY trial met: 58% relative reduction in annualized relapse rate in the low total dose treatment...

Novartis launches Extavia®, a new therapeutic option to help patients combat devastating symptoms of multiple sclerosis

›
# Multiple sclerosis (MS) causes progressive disability and affects 2.5 million people worldwide including many young adults[1] # Extavia of...

Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis

›
Cambridge, Mass., January 15, 2009 — Peptimmune, Inc. (“Peptimmune”), a privately held biotechnology company, announced today that it has gr...

New Interferon Formulations Promise to Eliminate Injections in Multiple Sclerosis Treatment

›
SAN DIEGO, CA January 12, 2009/MarketWire/-- Nerveda Inc. and Aegis Therapeutics LLC today announced preclinical results from their joint co...

Apitope and Merck Serono Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis

›
Apitope and Merck Serono to collaborate on development and commercialization of ATX-MS-1467, Apitope’s peptide therapeutic for the treatment...

Acorda expects to seek approval for drug

›
January 12, 2009 Acorda Therapeutics Inc., a Hawthorne-based biotech company, said that it is pushing ahead with plans to seek regulatory ap...

MS Relapse-Rate Higher in Adolescent-Onset Patients

›
By Michael Smith, North American Correspondent, MedPage Today Published: January 12, 2009 Reviewed by Zalman S. Agus, MD; Emeritus Professor...

UPDATE 1-Biogen moves long-acting Avonex to final trial-CEO

›
By Deena Beasley LOS ANGELES, Jan 7 (Reuters) - Biogen Idec Inc (BIIB.O: Quote, Profile, Research) has moved a long-acting version of its mu...

Immune Molecule Decreases Severity Of Multiple Sclerosis-like Disease In Mice

›
ScienceDaily (Jan. 4, 2009) — A group led by Dr. Cedric Raine at Albert Einstein College of Medicine have explored the expression of an immu...
Friday, December 12, 2008

First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a

›
* FTY720 significantly reduced annualized relapse rates by 52% (0.5 mg dose) and 38% (1.25 mg) vs. interferon beta-1a in one-year TRANSF...
Thursday, December 11, 2008

Elan seeks deals to raise cash

›
Tue Nov 18, 2008 6:11pm EST NEW YORK (Reuters) - Elan Corp Plc (ELN.N: Quote, Profile, Research, Stock Buzz)(ELN.I: Quote, Profile, Research...

MS services are poor

›
Greg Baxter greg.baxter@imt.ie Ireland has scored poorly, relative to the rest of Europe, on care for multiple sclerosis from the EU body Mu...

Environment Causes Increase In Multiple Sclerosis Among Women Only

›
17 Nov 2008 Gender has become a dominant factor in Multiple Sclerosis (MS) during the last decades. Already with a ratio of 3.2 to 1 MS is...
Monday, November 10, 2008

Multiple Sclerosis Progression Can Be Predicted With MRI

›
ScienceDaily (Nov. 6, 2008) — A new study published in Journal of Neuroimaging shows that MRI scans used on multiple sclerosis (MS) patients...

Avigen Announces Restructuring and Strategic Direction

›
ALAMEDA, Calif., Nov 3, 2008 (GlobeNewswire via COMTEX News Network) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating t...

Source MDx, Brigham and Women's Partner on Multiple Sclerosis Biomarker Discovery

›
[November 3, 2008] By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) - Source MDx has formed a partnership with Boston’s Brigham and ...

Virtual Reality Helps MS Patients Regain Stability While Walking

›
Medigait LLC announces the release of a new device that combines virtual reality programming and real-time motion detection into a cell-phon...
Friday, October 31, 2008

Interferon Could Be A Key To Preventing Or Treating Multiple Sclerosis

›
31 Oct 2008 Multiple sclerosis (MS) results when the body's own defense system attacks nerve fibers in the brain and spinal cord. Now ...